{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:11:00Z","timestamp":1784686260116,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004263","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio Grande do Sul","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2019.00712","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T04:24:17Z","timestamp":1571718257000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Carla Fernanda","family":"Nava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Selbach","family":"Scheffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Patr\u00edcia","family":"Cristo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Vaz","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Borsatto","family":"Zanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Costa","family":"Paix\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alceu","family":"Migliavaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ricardo","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia Silveira","family":"Graudenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Dora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Luiza","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","first-page":"3","article-title":"Thyroid carcinoma: epidemiology, histology, and diagnosis","volume":"13","author":"Shah","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in thyroid cancer incidence and mortality in the United States, 1974\u20132013","volume":"317","author":"Lim","year":"2017","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B5","doi-asserted-by":"publisher","first-page":"vii110","DOI":"10.1093\/annonc\/mds230","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Pacini","year":"2012","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1590\/S0004-27302013000400002","article-title":"Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus","volume":"57","author":"Ros\u00e1rio","year":"2013","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"E288","DOI":"10.1210\/jc.2010-1905","article-title":"Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer","volume":"96","author":"Antonelli","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40259-013-0049-y","article-title":"Sorafenib and thyroid cancer","volume":"27","author":"Fallahi","year":"2013","journal-title":"BioDrugs."},{"key":"B9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5306\/wjco.v8.i3.203","article-title":"Evolving role of Sorafenib in the management of hepatocellular carcinoma","volume":"8","author":"Ziogas","year":"2017","journal-title":"World J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/annonc\/mdu259","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Escudier","year":"2014","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3892\/ol.2017.6131","article-title":"Presurgical neoadjuvant targeted molecular therapy for kidney cancer with concomitant vena cava tumor embolus: a clinical study","volume":"14","author":"Guo","year":"2017","journal-title":"Oncol Lett"},{"key":"B15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1359-6349(09)70018-7","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1530\/ERC-15-0162","article-title":"MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma","volume":"23","author":"Romitti","year":"2016","journal-title":"Endocr Relat Cancer."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/thy.2011.0243","article-title":"Neoadjuvant chemotherapy in 29 patients with locally advanced follicular or hurthle cell thyroid carcinoma: a phase 2 study","volume":"22","author":"Besic","year":"2012","journal-title":"Thyroid"},{"key":"B19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1089\/thy.2012.0194","article-title":"Neoadjuvant chemotherapy in 16 patients with locally advanced papillary thyroid carcinoma","volume":"23","author":"Besic","year":"2013","journal-title":"Thyroid"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1089\/thy.1998.8.1113","article-title":"Effectiveness of preoperative radioactive iodine (131I) therapy for locally advanced papillary thyroid cancer: a case report","volume":"8","author":"Shingu","year":"1998","journal-title":"Thyroid"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1200\/JCO.2009.27.4225","article-title":"Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib","volume":"28","author":"Cleary","year":"2010","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijscr.2017.10.010","article-title":"Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: a case report","volume":"41","author":"Tsuboi","year":"2017","journal-title":"Int J Surg Case Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"370","DOI":"10.20945\/2359-3997000000046","article-title":"Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer","volume":"62","author":"Danilovic","year":"2018","journal-title":"Arch Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/hed.23619","article-title":"Management of invasive well-differentiated thyroid cancer: an American head and neck society consensus statement","volume":"36","author":"Shindo","year":"2014","journal-title":"Head Neck"},{"key":"B25","first-page":"166","article-title":"Thyroid carcinoma with tracheal or esophageal involvement: limited or maximal surgery?","volume":"113","author":"Melli\u00e8re","year":"1993","journal-title":"Surgery"},{"key":"B26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S0022-5223(97)70120-X","article-title":"Differentiated thyroid carcinoma with airway invasion: indication for tracheal resection based on the extent of cancer invasion","volume":"114","author":"Nishida","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B27","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/bjc.2011.55","article-title":"Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model","volume":"104","author":"Yuen","year":"2011","journal-title":"Br J Cancer"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00712\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T04:24:20Z","timestamp":1571718260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00712\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":27,"alternative-id":["10.3389\/fendo.2019.00712"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2019.00712","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"article-number":"712"}}